谷歌Chrome浏览器插件
订阅小程序
在清言上使用

Thyroid Diseases, Metformin and the AMP Kinase Pathway

TURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM(2021)

引用 0|浏览10
暂无评分
摘要
An increase in the adenosine monophosphate (AMP)/adenosine triphosphate ratio activates AMP-activated protein kinase (AMPK), leading to inhibition of the mammalian target of rapamycin signaling pathway that is associated with autophagy, mitochondriogenesis, glucose uptake, mRNA stabilization, and cell cycle regulation. Metformin activates AMPK and inhibits mitochondria! oxidative phosphorylation. Currently, there is an increasing interest in investigating the effects of metformin on thyroid diseases. Recent data show an association between metformin treatment and lower incidence of thyroid cancer, better survival of patients with thyroid cancer, and lower thyroid volume and nodule size. Insulin-like growth factor receptor and AKT pathways are the AMPK-independent mechanisms through which metformin acts on thyroid diseases. Although metformin has a promising role in adjuvant therapy for thyroid cancers, well-designed prospective trials are required before reaching a final decision.
更多
查看译文
关键词
Thyroid diseases, AMP-activated protein kinase pathway
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要